PMID- 12716487
OWN - NLM
STAT- MEDLINE
DCOM- 20031107
LR  - 20131121
IS  - 1079-9907 (Print)
IS  - 1079-9907 (Linking)
VI  - 23
IP  - 3
DP  - 2003 Mar
TI  - Effects of perioperative recombinant human IFN-gamma (rHuIFN-gamma) application 
      in vivo on T cell response.
PG  - 149-54
AB  - In spite of the well-known immunoregulatory effects of recombinant human 
      interferon-gamma (rHuIFN-gamma), in vitro clinical trials in trauma patients 
      remain inconclusive. In vitro studies have shown that IFN-gamma has an effect on 
      lymphocyte responses in addition to immunomodulatory effects on the 
      monocyte/macrophage system. To investigate the in vivo effect of rHuIFN-gamma 
      perioperatively on lymphocyte behavior in surgical patients, we studied 46 
      anergic patients undergoing major surgery. Treated patients (T, n = 24) received 
      100 microg rHuIFN-gamma subcutaneously (s.c.), and control patients (C, n = 22) 
      received a placebo on preoperative days -7, -5, and -3 in a controlled, 
      double-blinded placebo trial. Whole blood cultures were stimulated with mitogen 
      on perioperative days, and cytokines were investigated in the supernatants. 
      Interleukin-2 receptor (IL-2R) levels were significantly elevated in the 
      treatment arm during the postoperative period (p < 0.05). The postoperative 
      enhancement of IL-4 in C was completely attenuated in T (p < 0.05). IL-2 levels 
      were elevated perioperatively in T but not in C. No significant effect of 
      rHuIFN-gamma could be demonstrated on IL-10 or lymphocyte proliferation in vitro. 
      From this pilot study, we conclude that preoperative in vivo immunomodulation of 
      lymphocyte function with rHuIFN-gamma in anergic patients is effective. It 
      improves immunoreactivity, as shown by elevated IL-2R levels. Elevated IL-2 and 
      suppressed IL-4 levels indicate a shift toward a Th1-driven lymphocyte response.
FAU - Licht, A-K
AU  - Licht AK
AD  - Department of Surgery, Ludwig-Maximilians University Munich, Klinikum 
      Grosshadern, 81377 Munich, Germany.
FAU - Schinkel, C
AU  - Schinkel C
FAU - Zedler, S
AU  - Zedler S
FAU - Schinkel, S
AU  - Schinkel S
FAU - Faist, E
AU  - Faist E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (Anticoagulants)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-2)
RN  - 0 (Phytohemagglutinins)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Recombinant Proteins)
RN  - 130068-27-8 (Interleukin-10)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9G34HU7RV0 (Edetic Acid)
SB  - IM
MH  - Aged
MH  - Anticoagulants/pharmacology
MH  - Cell Division/drug effects
MH  - Cytokines/blood
MH  - Dose-Response Relationship, Immunologic
MH  - Double-Blind Method
MH  - Edetic Acid/pharmacology
MH  - Female
MH  - Humans
MH  - Interferon-gamma/immunology/*therapeutic use
MH  - Interleukin-10/biosynthesis/immunology
MH  - Interleukin-2/biosynthesis/immunology
MH  - Interleukin-4/biosynthesis/immunology
MH  - Lymphocyte Activation/drug effects/immunology
MH  - Male
MH  - Monocytes/drug effects/metabolism
MH  - Perioperative Care
MH  - Phytohemagglutinins/pharmacology
MH  - Plasma/cytology/drug effects/immunology
MH  - Prospective Studies
MH  - Receptors, Interleukin-2/biosynthesis/immunology
MH  - Recombinant Proteins
MH  - T-Lymphocytes/cytology/*drug effects/immunology
MH  - Time Factors
EDAT- 2003/04/30 05:00
MHDA- 2003/11/08 05:00
CRDT- 2003/04/30 05:00
PHST- 2003/04/30 05:00 [pubmed]
PHST- 2003/11/08 05:00 [medline]
PHST- 2003/04/30 05:00 [entrez]
AID - 10.1089/107999003321532484 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 2003 Mar;23(3):149-54. doi: 
      10.1089/107999003321532484.